Withdrawal of cerivastatin from the world market
Open accessThe DOI matches its Crossref record; 7 of the 8 references it cites were found in a registry or an index.
Abstract
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three important questions raised by this withdrawal. Should we continue to approve drugs on surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We conclude that decisions regarding the use of drugs should be based on direct evidence from long-term clinical outcome trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cerivastatin (Section 7.7) and terfenadine (Section 7.9) are metabolism- and interaction-dependent failures, in which a cytochrome P450 drug interaction rather than body size dictated the clinically decisive exposure.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neither standard CYP3A4-centric DDI screening (cerivastatin is principally a CYP2C8 substrate) nor allometric extrapolation captured this liability.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rhabdomyolysis risk was concentrated in patients co-prescribed gemfibrozil, an inhibitor of both CYP2C8-mediated cerivastatin metabolism and OATP1B1-mediated hepatic uptake, resulting in several-fold increases in exposure relative to monotherapy [79].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The case is now a canonical example of why ECCS classification, transporter-DDI screening, and post-marketing pharmacoepidemiology must be integrated alongside any allometric or PBPK extrapolation [41,43,44,79].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Cerivastatin, withdrawn worldwide in 2001 because of a disproportionate rate of fatal rhabdomyolysis, illustrates how a pharmacokinetic interaction that preclinical species do not flag can dominate the clinical safety profile.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Natural Statins and Stroke Risk
Furberg, C. D. (1999) · Circulation · doi:10.1161/01.cir.99.2.185 · Cited by 133 · cited 1×
“have been shown to reduce the risk of mortality and/or major coronary events [3].”
BackgroundSelf-citationDebate: The slippery slope of surrogate outcomes
D'Agostino, R. B. (2000) · Trials · doi:10.1186/cvm-1-2-076 · Cited by 46 · cited 1×
“First, experience indicates that changes in surrogate markers are poor predictors of clinical efficacy [6,7].”
BackgroundBayer faces potential fine over cholesterol lowering drug
Tuffs, A. (2001) · BMJ · doi:10.1136/bmj.323.7310.415a · Cited by 11
The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions
Furberg, C. D. (2001) · Trials · doi:10.1186/cvm-2-3-107 · Cited by 8
Self-citationFurberg, C. D. (2001) · Cited by 3
Self-citationUS consumer groups allege misleading drug claims
Gottlieb, S. (2001) · BMJ · doi:10.1136/bmj.323.7310.415 · Cited by 3
Research works printed but not linked: 5
- American Heart Association and American College of Cardiology Advisory ACC and AHA reassure patients about statins' effectiveness, safety. Physicians patients urged to discuss concerns side effects and options for lowering cholesterol. News Release August 30, 2001
- Fuhrmans V Winslow R Harris G Bayer recall spurs Europe to wide review. Wall Street Journal, August 10, 2001 A3
- Division of Drug Marketing Advertising and Communications of the US Food and Drug Administration Warning letter to Novartis Pharmaceuticals Corporation. Re: Lescol (fluvastatin sodium) capsules. January 21, 1999
- Division of Drug Marketing Advertising and Communications of the US Food and Drug Administration Warning letter to Pfizer Inc. Re: Lipitor (atorvastatin calcium) tablets. July 12, 2001
- Pfeffer MA Keech A Cobbe SM Tonkin A Byington RP Braunwald E Friedman C Sachs FM Prospective Pravastatin Pooling (PPP) project: the tolerability and safety of pravastatin based on a 112,000 patient-year experience in placebo-controlled trials [abstract]. Eur Heart J 2001 22(suppl) 271
Cited by
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
“Creatine kinase ratio, mean (SD) [range]* 274 (89) [15-1780]”
BackgroundThe safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Metadata
- Authors
- Furberg, C. D., & Pitt, B.
- Affiliations
- Wake Forest University Health Sciences (US)
- University of Michigan (US)
- Corresponding author
- Furberg, Curt D
- ORCID
- Pitt, Bertram
- Venue
- Trials
- Published
- 2001-09-26
- Volume
- 2
- Issue
- 5
- Pages
- 205-207
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC59524
- OpenAlex
- W1560686237
- Cited by
- 400
- References
- 7
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 12 · 2023: 24 · 2022: 16 · 2021: 13 · 2020: 15 · 2019: 22 · 2018: 24 · 2017: 15 · 2016: 21 · 2015: 25 · 2014: 19 · 2013: 15 · 2012: 20
- FWCI
- 20.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Trials (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- cerivastatin, drug withdrawal, rhabdomyolysis, statins, gemfibrozil, drug safety, drug approval, risk-benefit assessment, drug interchangeability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Withdrawal of cerivastatin from the world market. https://app.cochat.ai/papers/10.1186/cvm-2-5-205
- The paper
- Furberg, C. D., & Pitt, B. (2001). Withdrawal of cerivastatin from the world market. Trials. https://doi.org/10.1186/cvm-2-5-205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.